Table 4.
Selected current DNA vaccines progressing through Phase I to III clinical trials.
| Human | Product name | Vector name | Vaccine formulation | Delivery method | Clinical status | Trial number | Sponsor |
|---|---|---|---|---|---|---|---|
| DNA vaccine priming only | |||||||
| HIV infection (Prophylactic vaccine) | PENNVAX®-B | – | DNA vaccine | CELLECTRA® intramuscular electroporation device | Phase I | NCT01082692 | Inovio Pharmaceuticals |
| PENNVAX®-GP | – | DNA vaccine + plasmid cytokine adjuvant (IL-12) | Intradermal injection/ intramuscular injection with CELLECTRA® electroporation | Phase I | NCT02431767 | Inovio Pharmaceuticals | |
| Malaria (Prophylactic vaccine) | EP-1300 | DNA vaccine | Intramuscular injection with electroporation via TriGrid™ Delivery System (TDS) | Phase I | NCT01169077 | KAEL-GemVax | |
| Hepatitis B (Therapeutic immunotherapy) | INO-1800® | – | DNA vaccine + plasmid cytokine adjuvant (IL-12) | CELLECTRA® electroporation device | Phase I | NCT02431312 | Inovio Pharmaceuticals |
| Zika virus infections (Prophylactic vaccine) | GLS-5700® | pGX7201 | DNA vaccine only | Intradermal injection with CELLECTRA® electroporation | Phase I | NCT02809443, NCT02887482 | GeneOne Life Science, Inovio Pharmaceuticals |
| Middle East respiratory syndrome coronavirus (MERS CoV) (Prophylactic vaccine) | GLS-5300® | – | DNA vaccine only | Intramuscular injection with CELLECTRA® electroporation | Phase I | NCT02670187 | GeneOne Life Science, Inovio Pharmaceuticals |
| Influenza A H5N1 and H1N1 subtypes (Prophylactic vaccine) | INO-3510® | – | DNA vaccine only | Intradermal injection with CELLECTRA® electroporation | Phase I | NCT01405885 | Inovio Pharmaceuticals |
| Viral hemorrhagic fever with renal syndrome (Prophylactic vaccine) | HTNV/PUUV DNA Vaccine | pWRG/HTN-M(co)/pWRG/PUUV-M(s2) | DNA vaccine only | Intramuscular injection with electroporation via TriGrid™ Delivery System (TDS) | Phase II | NCT02116205 | Ichor Medical Systems US Army Medical Research and Materiel Command |
| Cytomegalovirus infection in hematopoietic cell transplantation/solid organ (kidney) transplantation | ASP0113 | TransVax | DNA vaccine with poloxamer-based CRLL1005 delivery system | Intramuscular injection | Phase III | NCT01877655, NCT01974206 | Astellas, Pharma Vical |
| HSV-2 infection (Therapeutic vaccine) | herpes simplex bivalent DNA vaccine | VCL-HB01 | DNA vaccine only | Intramuscular injection | Phase II | NCT02837575 | Vical |
| DNA vaccine priming and other vaccine boosting | |||||||
| HIV infection (Prophylactic vaccine) | GOVX-B11 | pGA2/JS7 | DNA vaccine prime + MVA vaccine boost | Intramuscular injection | Phase II | NCT00820846 | GeoVax |
| HIV infection (Prophylactic vaccine) | PENNVAX®-G | – | DNA vaccine prime + MVA-CMDR vaccine boost | Intramuscular delivery by Biojector 2000® needleless device/CELLECTRA® intramuscular electroporation device | Phase I | NCT01260727 | Inovio Pharmaceuticals |
| Malaria (Prophylactic vaccine) | – | – | DNA vaccine prime + adenovirus type 5 vaccine (Ad) boost | Intramuscular delivery by Biojector 2000® needleless device | Phase I/IIa | NCT00870987 | Vical, U.S. Army Medical Research and Materiel Command |